PSMA-targeted radiopharmaceuticals for prostate cancer diagnosis and therapy
JD Oldan, F Almaguel, AF Voter, A Duran… - The Cancer …, 2024 - journals.lww.com
Prostate cancer (PCa) is the most common noncutaneous malignancy in men. Until recent
years, accurate imaging of men with newly diagnosed PCa, or recurrent or low-volume …
years, accurate imaging of men with newly diagnosed PCa, or recurrent or low-volume …
PSMA radioligand therapy in prostate cancer: where are we and where are we heading?
LS Almeida… - Clinical Nuclear …, 2024 - journals.lww.com
Diagnosis and treatment of prostate cancer are complex and very challenging, being a
major health care burden. The efficacy of radioligand therapy with prostate-specific …
major health care burden. The efficacy of radioligand therapy with prostate-specific …
[177Lu] Lu-PSMA-617 versus docetaxel in chemotherapy-naïve metastatic castration-resistant prostate cancer: final survival analysis of a phase 2 randomized …
The prostate-specific membrane antigen (PSMA) inhibitor [177Lu] Lu-PSMA-617 has been
previously demonstrated to be noninferior to docetaxel in achieving a biochemical response …
previously demonstrated to be noninferior to docetaxel in achieving a biochemical response …
PSMA-based therapeutics for prostate cancer
PV Stamatakos, C Fragkoulis, A Leventi… - Expert Opinion on …, 2024 - Taylor & Francis
ABSTRACT Introduction The prostate cancer (PCa) consists the most frequently diagnosed
malignancy of urogenital system in males. Traditionally, treatment of localized PCa was …
malignancy of urogenital system in males. Traditionally, treatment of localized PCa was …
Assessment of the therapeutic efficacy of [177Lu] Lu-PSMA-X compared to taxane chemotherapy in taxane-chemo-naïve patients with metastatic castration-resistant …
LS Almeida, I García Megías… - European Journal of …, 2024 - Springer
Materials and methods Searches in several bibliographic databases were made using
relevant key words, and articles published up to March 2024 were included. The endpoints …
relevant key words, and articles published up to March 2024 were included. The endpoints …
[177Lu]Lu-PSMA-617 as first-line systemic therapy in patients with metastatic castration-resistant prostate cancer: a real-world study
S Satapathy, MP Yadav, S Ballal, RK Sahoo… - European Journal of …, 2024 - Springer
Abstract Purpose The use of [177Lu] Lu-PSMA-617 radioligand therapy has become
increasingly recognized as a viable therapeutic approach for patients in the advanced …
increasingly recognized as a viable therapeutic approach for patients in the advanced …
[HTML][HTML] Review on the Increasing Role for PSMA-Based Radioligand Therapy in Prostate Cancer
FE von Eyben, I Virgolini, R Baum - Cancers, 2024 - mdpi.com
Simple Summary In 2021, the randomized controlled trial VISION showed that prostate-
specific membrane antigen (PSMA)-based third-line radioligand therapy as monotherapy for …
specific membrane antigen (PSMA)-based third-line radioligand therapy as monotherapy for …
Clinical Management of Advanced Prostate Cancer: Where Does Radiopharmaceutical Therapy Fit in the Treatment Algorithm?
P Viscuse, M Devitt, R Dreicer - Journal of Nuclear Medicine, 2024 - Soc Nuclear Med
Most men with newly appreciated metastatic prostate cancer are optimally treated with a
backbone consisting of androgen receptor–directed therapy with or without taxane …
backbone consisting of androgen receptor–directed therapy with or without taxane …
Promising Therapeutic Activity of 177Lu-PSMA-617 in Synchronous High-Volume Metastatic Hormone-Sensitive Prostate Cancer: A Pilot Experience
S Satapathy, MP Yadav, S Ballal… - Clinical Nuclear …, 2024 - journals.lww.com
Purpose 177 Lu-PSMA-617 has been shown to improve survival outcomes in patients with
end-stage metastatic castration-resistant prostate cancer. However, data in earlier lines …
end-stage metastatic castration-resistant prostate cancer. However, data in earlier lines …
177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: A Review of the Evidence and Implications for Canadian Clinical Practice
Prostate-specific membrane antigen (PSMA) is highly expressed in prostate cancer and a
therapeutic target. Lutetium-177 (177Lu)-PSMA-617 is the first radioligand therapy to be …
therapeutic target. Lutetium-177 (177Lu)-PSMA-617 is the first radioligand therapy to be …